Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Measles virus (MeV) surface antigens, specifically the Hemagglutinin (H) and Fusion (F) glycoproteins, are the primary mediators of viral entry into host cells. The H protein is responsible for recognizing and binding to specific host receptors, including CD150 (SLAM) on immune cells and Nectin-4 on epithelial cells (Citations: PubMed: 22016511, UniProt: P08362). Once bound, the H protein triggers the F protein to undergo a dramatic structural rearrangement that merges the viral and cellular membranes (Citations: PubMed: 21835787, UniProt: P03372). This process is essential for the delivery of the viral ribonucleoprotein complex into the host cytoplasm to initiate replication. These glycoproteins are the major targets for neutralizing antibodies induced by natural infection or vaccination with the live-attenuated measles vaccine (Citations: NIH: StatPearls - Measles). In addition to vaccines, these proteins are targets for experimental antiviral therapies, such as small-molecule fusion inhibitors like ERDRP-0519 and various monoclonal antibodies (Citations: PubMed: 25855243). Because they are exposed on the virion surface, they are also the primary site of selective pressure for the virus to evolve and escape immune detection. Understanding the interplay between H and F is crucial for developing treatments for severe measles complications, such as pneumonia and subacute sclerosing panencephalitis.
Neutralization of viral attachment by blocking Hemagglutinin-receptor interaction and inhibition of membrane fusion by preventing Fusion protein conformational changes.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Measles virus Hemagglutinin (H) and Fusion (F) glycoprotein (MeV H/F).